X4 PharmaceuticalsXFOR
Recorded

X4 Pharmaceuticals Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration24 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

JamesAnalyst

Great. Welcome everyone to the next session here at the Healthcare Conference. Excited to be joined by X4 Pharmaceuticals. We have Executive Chairman Adam Craig, and interesting time for you guys. Maybe I was thinking we can kind of just start. Obviously, a lot has kind of gone on in terms of you guys coming in, kind of transforming the company. Maybe just kind of like set the stage of everything that's happened over maybe like the last year or so, and kind of what got you guys excited to join, and kind of what's the path forward from here?

Adam CraigExecutive Chairman

Well, first of all, thank you for inviting us. We're pleased to be here. As David, CFO, who's with me today, David Kirske, and I have known about this company for three or four years ago. We looked at the company when we were at CTI BioPharma.

Adam CraigExecutive Chairman

because we always thought mavorixafor was a good agent, an active agent, and an agent in which it could be developed successfully in chronic neutropenia.

Adam CraigExecutive Chairman

About a year ago, the opportunity came along with a new investment that was made to work with some new investors and come into the company. In July of last year, and then in August, there was a refinancing and we joined as a new management team. We haven't been disappointed. Mavorixafor is what we thought it was.

Adam CraigExecutive Chairman

Yeah. Once you get inside, you see the data.

Adam CraigExecutive Chairman

We have spent the last year really sort of making the company more efficient, reducing costs. We've reduced headcount. We've changed the management team.

Adam CraigExecutive Chairman

We've brought in some people outside with certain expertise. All that has led to us focusing on the enrollment of our pivotal phase III trial, the 4WARD trial.

Adam CraigExecutive Chairman

Which is, as I've said repeatedly, is the main focus of the company that employees need to think every day, what are they doing towards that trial.

Adam CraigExecutive Chairman

With that, we are looking forward to completing enrollment by the end of this year.

Adam CraigExecutive Chairman

Then that would lead us to having topline data for the phase III in chronic neutropenia in the first quarter of 2028.

JamesAnalyst

Awesome. On the trial, earlier this fall, you guys lowered the end slightly for the trial. Maybe just kind of talk about the decision to do that.

Adam CraigExecutive Chairman

The trial when we joined, it was grossly overpowered.

Adam CraigExecutive Chairman

The 176 patients, the powering of each of the primary endpoints was greater than 96%. We became confident that we were enrolling the correct patients.

Adam CraigExecutive Chairman

The characteristics of the patients were correct, and that the patients were sick. This is something the FDA said to us, "You've got to enroll sick patients in whom you can show a difference.

Adam CraigExecutive Chairman

When we saw that happening, we took another look at the sample size, and we saw that we could retain 89% powering for the infection endpoint and 93% powering for the ANC endpoint, if we took the sample down to size to 126. It really was for two reasons. One is it obviously makes good, it's prudent, it's good business sense not to over-enroll a trial. It's a double-blind, placebo-controlled trial, and I don't want to enroll more patients than we actually need Yeah to test the hypothesis.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day